<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">

<pdf2xml producer="poppler" version="23.12.0">
<page number="1" position="absolute" top="0" left="0" height="792" width="600">
	<fontspec id="0" size="10" family="Minion" color="#231f20"/>
	<fontspec id="1" size="9" family="Minion" color="#231f20"/>
	<fontspec id="2" size="9" family="Minion" color="#231f20"/>
	<fontspec id="3" size="9" family="MinionProMath" color="#231f20"/>
	<fontspec id="4" size="8" family="LucidaNewMath-Symbol" color="#231f20"/>
	<fontspec id="5" size="5" family="LucidaNewMath-Symbol" color="#231f20"/>
	<fontspec id="6" size="4" family="LucidaNewMath-Symbol" color="#231f20"/>
	<fontspec id="7" size="8" family="Minion" color="#231f20"/>
	<fontspec id="8" size="10" family="Minion" color="#231f20"/>
	<fontspec id="9" size="8" family="MinionProMath" color="#231f20"/>
	<fontspec id="10" size="10" family="Minion" color="#000000"/>
	<fontspec id="11" size="10" family="MinionProMath" color="#231f20"/>
	<fontspec id="12" size="9" family="LucidaNewMath-Symbol" color="#231f20"/>
<text top="45" left="51" width="5" height="9" font="0">4</text>
<text top="45" left="406" width="143" height="9" font="0">International Journal of Hepatology</text>
<text top="74" left="51" width="240" height="9" font="1">Table 4: Radiologic evolution after transarterial chemoemboliza-</text>
<text top="84" left="51" width="47" height="9" font="2">tion (TACE).</text>
<text top="103" left="53" width="29" height="9" font="2">Variable</text>
<text top="100" left="274" width="5" height="12" font="3"><i>n</i></text>
<text top="115" left="53" width="56" height="9" font="2">Tumor size (%)</text>
<text top="128" left="63" width="37" height="9" font="2">Reduction</text>
<text top="126" left="102" width="5" height="12" font="3"><i>&gt;</i></text>
<text top="128" left="107" width="21" height="9" font="2">5 mm</text>
<text top="128" left="263" width="26" height="9" font="2">13 (43)</text>
<text top="140" left="63" width="40" height="9" font="2">Stability +/</text>
<text top="139" left="103" width="6" height="10" font="4"><i>−</i></text>
<text top="140" left="109" width="21" height="9" font="2">5 mm</text>
<text top="140" left="265" width="22" height="9" font="2">6 (20)</text>
<text top="153" left="63" width="42" height="9" font="2">Progression</text>
<text top="151" left="107" width="5" height="12" font="3"><i>&gt;</i></text>
<text top="153" left="112" width="21" height="9" font="2">5 mm</text>
<text top="153" left="265" width="22" height="9" font="2">5 (17)</text>
<text top="165" left="63" width="36" height="9" font="2">Unknown</text>
<text top="164" left="99" width="4" height="7" font="5"><i>∗</i></text>
<text top="165" left="265" width="22" height="9" font="2">6 (20)</text>
<text top="178" left="53" width="59" height="9" font="2">New lesions (%)</text>
<text top="190" left="63" width="11" height="9" font="2">No</text>
<text top="190" left="263" width="26" height="9" font="2">15 (50)</text>
<text top="203" left="63" width="11" height="9" font="2">Yes</text>
<text top="203" left="265" width="22" height="9" font="2">9 (30)</text>
<text top="215" left="63" width="36" height="9" font="2">Unknown</text>
<text top="213" left="99" width="4" height="7" font="5"><i>∗</i></text>
<text top="215" left="265" width="22" height="9" font="2">6 (20)</text>
<text top="228" left="53" width="76" height="9" font="2">Overall response (%)</text>
<text top="240" left="63" width="94" height="9" font="2">Regression (size reduction</text>
<text top="238" left="159" width="5" height="12" font="3"><i>&gt;</i></text>
<text top="240" left="164" width="125" height="9" font="2">5 mm and no new lesions) 10 (33)</text>
<text top="252" left="63" width="89" height="9" font="2">Stability (size stability +/</text>
<text top="251" left="151" width="6" height="10" font="4"><i>−</i></text>
<text top="252" left="158" width="94" height="9" font="2">5 mm and no new lesions)</text>
<text top="252" left="265" width="22" height="9" font="2">4 (13)</text>
<text top="265" left="63" width="177" height="9" font="2">Progression (size progression and/or new lesions)</text>
<text top="265" left="263" width="26" height="9" font="2">10 (33)</text>
<text top="277" left="63" width="36" height="9" font="2">Unknown</text>
<text top="277" left="265" width="22" height="9" font="2">6 (20)</text>
<text top="290" left="53" width="91" height="9" font="2">Downstaging (6 patients)</text>
<text top="302" left="63" width="11" height="9" font="2">Yes</text>
<text top="302" left="265" width="22" height="9" font="2">3 (50)</text>
<text top="315" left="63" width="11" height="9" font="2">No</text>
<text top="315" left="265" width="22" height="9" font="2">3 (50)</text>
<text top="325" left="51" width="4" height="6" font="6"><i>∗</i></text>
<text top="328" left="55" width="227" height="8" font="7">These patients did not have imaging after TACE before transplantation.</text>
<text top="352" left="95" width="151" height="9" font="1">Table 5: Orthotopic liver transplantation.</text>
<text top="370" left="53" width="29" height="9" font="2">Variable</text>
<text top="368" left="265" width="5" height="12" font="3"><i>n</i></text>
<text top="383" left="53" width="147" height="9" font="2">Patients with OLT/Patients listed for OLT</text>
<text top="383" left="257" width="20" height="9" font="2">26/30</text>
<text top="396" left="53" width="123" height="9" font="2">Mean waiting time in days (range)</text>
<text top="396" left="246" width="43" height="9" font="2">110 (4–460)</text>
<text top="408" left="53" width="104" height="9" font="2">Milan at transplantation (%)</text>
<text top="421" left="63" width="8" height="9" font="2">In</text>
<text top="421" left="254" width="26" height="9" font="2">22 (85)</text>
<text top="433" left="63" width="14" height="9" font="2">Out</text>
<text top="433" left="265" width="4" height="9" font="2">4</text>
<text top="446" left="63" width="122" height="9" font="2">Progression beyond Milan criteria</text>
<text top="446" left="265" width="4" height="9" font="2">2</text>
<text top="458" left="63" width="146" height="9" font="2">Failed downstaging within Milan criteria</text>
<text top="458" left="265" width="4" height="9" font="2">2</text>
<text top="491" left="51" width="240" height="9" font="0">criteria but 4 patients (15%) exceeded Milan criteria; tumor</text>
<text top="503" left="51" width="240" height="9" font="0">growth from within to beyond Milan criteria after being</text>
<text top="514" left="51" width="240" height="9" font="0">listed was observed in 2 patients, downstaging failed in</text>
<text top="526" left="51" width="240" height="9" font="0">2 others. These patients were transplanted despite being</text>
<text top="537" left="51" width="240" height="9" font="0">beyond Milan criteria either because the tumor was at the</text>
<text top="548" left="51" width="240" height="9" font="0">margin of the criteria or because of uncertainty about the</text>
<text top="560" left="51" width="139" height="9" font="0">malignant nature of some nodules.</text>
<text top="586" left="51" width="240" height="9" font="8"><i>3.8. Pathology of Explanted Livers. </i>The histopathologic anal-</text>
<text top="597" left="51" width="240" height="9" font="0">ysis of the 26 explanted livers showed complete tumoral</text>
<text top="608" left="51" width="240" height="9" font="0">necrosis in 10 cases (42%) and partial necrosis in 15 cases</text>
<text top="620" left="51" width="240" height="9" font="0">(48%). The mean Edmondson score of patients with viable</text>
<text top="631" left="51" width="240" height="9" font="0">cancer was 2,5/4. Microvascular invasion was observed in</text>
<text top="643" left="51" width="240" height="9" font="0">3 cases and macrovascular invasion in one patient. In the</text>
<text top="654" left="51" width="240" height="9" font="0">patients transplanted exceeding Milan criteria just before</text>
<text top="665" left="51" width="240" height="9" font="0">OLT (4 cases), 1 had complete tumoral necrosis (a successful</text>
<text top="677" left="51" width="240" height="9" font="0">downstaging attempt) and 3 patients (75%) had HCC that</text>
<text top="688" left="51" width="223" height="9" font="0">remained outside Milan criteria at pathological analysis.</text>
<text top="699" left="66" width="225" height="9" font="0">In the 10 livers where complete HCC necrosis was</text>
<text top="711" left="51" width="240" height="9" font="0">observed, 9 were within Milan before transplantation. Seven</text>
<text top="722" left="51" width="240" height="9" font="0">patients had a regression of the tumor following TACE, 2 had</text>
<text top="733" left="51" width="187" height="9" font="0">stable lesions, and 1 had new lesions identified.</text>
<text top="74" left="309" width="240" height="9" font="1">Table 6: Characteristics of patients with and without cancer recur-</text>
<text top="84" left="309" width="240" height="9" font="2">rence after OLT (mean follow-up 56 months; range: 6–142 months).</text>
<text top="103" left="437" width="36" height="9" font="2">No cancer</text>
<text top="114" left="436" width="38" height="9" font="2">recurrence</text>
<text top="103" left="491" width="25" height="9" font="2">Cancer</text>
<text top="114" left="485" width="38" height="9" font="2">recurrence</text>
<text top="106" left="533" width="5" height="12" font="3"><i>P</i></text>
<text top="107" left="538" width="4" height="7" font="5"><i>∗</i></text>
<text top="125" left="311" width="5" height="12" font="3"><i>n</i></text>
<text top="127" left="451" width="9" height="9" font="2">21</text>
<text top="127" left="502" width="4" height="9" font="2">5</text>
<text top="140" left="311" width="91" height="9" font="2">Tumor response to TACE</text>
<text top="153" left="321" width="84" height="9" font="2">regression/stability (%)</text>
<text top="153" left="442" width="26" height="9" font="2">15 (71)</text>
<text top="153" left="502" width="4" height="9" font="2">0</text>
<text top="153" left="530" width="15" height="9" font="2">.051</text>
<text top="166" left="321" width="42" height="9" font="2">Progression</text>
<text top="166" left="444" width="22" height="9" font="2">2 (10)</text>
<text top="166" left="493" width="22" height="9" font="2">4 (80)</text>
<text top="179" left="321" width="50" height="9" font="2">Not evaluated</text>
<text top="179" left="444" width="22" height="9" font="2">4 (19)</text>
<text top="179" left="493" width="22" height="9" font="2">1 (20)</text>
<text top="192" left="311" width="108" height="9" font="2">Milan criteria before OLT (%)</text>
<text top="205" left="321" width="47" height="9" font="2">within Milan</text>
<text top="205" left="442" width="26" height="9" font="2">19 (90)</text>
<text top="205" left="493" width="22" height="9" font="2">3 (60)</text>
<text top="205" left="528" width="19" height="9" font="2">.1548</text>
<text top="218" left="321" width="50" height="9" font="2">outside Milan</text>
<text top="218" left="444" width="22" height="9" font="2">2 (10)</text>
<text top="218" left="493" width="22" height="9" font="2">2 (40)</text>
<text top="231" left="311" width="115" height="9" font="2">Pathological tumor analysis (%)</text>
<text top="244" left="321" width="64" height="9" font="2">complete necrosis</text>
<text top="244" left="442" width="26" height="9" font="2">10 (48)</text>
<text top="244" left="502" width="4" height="9" font="2">0</text>
<text top="244" left="530" width="15" height="9" font="2">.066</text>
<text top="257" left="321" width="76" height="9" font="2">microscopic invasion</text>
<text top="257" left="453" width="4" height="9" font="2">0</text>
<text top="257" left="493" width="22" height="9" font="2">3 (60)</text>
<text top="257" left="530" width="15" height="9" font="2">.004</text>
<text top="270" left="311" width="34" height="9" font="2">Mortality</text>
<text top="270" left="444" width="22" height="9" font="2">2 (10)</text>
<text top="270" left="493" width="22" height="9" font="2">4 (80)</text>
<text top="270" left="530" width="15" height="9" font="2">.002</text>
<text top="281" left="309" width="4" height="6" font="6"><i>∗</i></text>
<text top="284" left="313" width="32" height="8" font="7">One sided</text>
<text top="282" left="347" width="4" height="10" font="9"><i>P</i></text>
<text top="284" left="352" width="142" height="8" font="7">-values calculated using the Fisher exact test.</text>
<text top="307" left="309" width="86" height="9" font="8"><i>3.9. Follow-Up. </i>Table</text>
<text top="307" left="397" width="5" height="9" font="10"><a href="">6</a></text>
<text top="307" left="405" width="144" height="9" font="0">summarizes patients’ characteristics</text>
<text top="318" left="309" width="240" height="9" font="0">after OLT with a mean follow-up of 56 months (range: 6–</text>
<text top="330" left="309" width="240" height="9" font="0">142 months). At follow-up, we identified 21 patients (81%)</text>
<text top="341" left="309" width="240" height="9" font="0">without cancer recurrence and 5 with cancer recurrence</text>
<text top="352" left="309" width="240" height="9" font="0">(19%). In patients identified with cancer recurrence, 3 (60%)</text>
<text top="364" left="309" width="240" height="9" font="0">had cancer in the transplanted liver and 2 (40%) had lung</text>
<text top="375" left="309" width="240" height="9" font="0">metastasis. Mean time to recurrence was 13.8 months (range</text>
<text top="386" left="309" width="58" height="9" font="0">6–22 months).</text>
<text top="398" left="324" width="225" height="9" font="0">Patients without cancer recurrence had more tumoral</text>
<text top="409" left="309" width="240" height="9" font="0">regression/stability after TACE than patients with cancer</text>
<text top="421" left="309" width="112" height="9" font="0">recurrence (71% versus 0%;</text>
<text top="418" left="423" width="6" height="13" font="11"><i>P</i></text>
<text top="419" left="432" width="7" height="12" font="12"><i>=</i></text>
<text top="418" left="442" width="2" height="13" font="11"><i>.</i></text>
<text top="421" left="444" width="105" height="9" font="0">051). In addition, patients</text>
<text top="432" left="309" width="240" height="9" font="0">with no tumoral recurrence were almost all within Milan</text>
<text top="443" left="309" width="240" height="9" font="0">criteria before transplantation (90%) as opposed to patients</text>
<text top="455" left="309" width="240" height="9" font="0">with tumoral recurrence (60%). Therefore, Milan status was</text>
<text top="466" left="309" width="240" height="9" font="0">associated to a relative risk of cancer recurrence posttrans-</text>
<text top="477" left="309" width="240" height="9" font="0">plantation of 6.33 with a 95% CI (1.53–26.18). Patients with</text>
<text top="489" left="309" width="240" height="9" font="0">no cancer recurrence showed more complete necrosis (48%</text>
<text top="500" left="309" width="42" height="9" font="0">versus 0%;</text>
<text top="498" left="353" width="6" height="13" font="11"><i>P</i></text>
<text top="499" left="362" width="7" height="12" font="12"><i>=</i></text>
<text top="498" left="371" width="2" height="13" font="11"><i>.</i></text>
<text top="500" left="374" width="175" height="9" font="0">066) and significantly less microscopic inva-</text>
<text top="511" left="309" width="85" height="9" font="0">sion (0% versus 60%;</text>
<text top="509" left="396" width="6" height="13" font="11"><i>P</i></text>
<text top="510" left="405" width="7" height="12" font="12"><i>=</i></text>
<text top="509" left="414" width="2" height="13" font="11"><i>.</i></text>
<text top="511" left="417" width="118" height="9" font="0">004) on pathological analysis.</text>
<text top="523" left="324" width="225" height="9" font="0">Six patients died (23%) at follow-up: 1 from postoper-</text>
<text top="534" left="309" width="240" height="9" font="0">ative complications, 4 from cancer recurrence, and 1 from</text>
<text top="546" left="309" width="240" height="9" font="0">cirrhosis associated with hepatitis C 7 years posttransplanta-</text>
<text top="557" left="309" width="49" height="9" font="0">tion (Figure</text>
<text top="557" left="361" width="5" height="9" font="10"><a href="">1</a></text>
<text top="557" left="366" width="183" height="9" font="0"><a href="">). </a>Therefore, survival of patients with tumor</text>
<text top="568" left="309" width="240" height="9" font="0">recurrence was poor, mortality was significantly lower in</text>
<text top="580" left="309" width="240" height="9" font="0">patients without cancer recurrence compared to patients</text>
<text top="591" left="309" width="164" height="9" font="0">with cancer recurrence (10% versus 80%;</text>
<text top="589" left="475" width="6" height="13" font="11"><i>P</i></text>
<text top="590" left="484" width="7" height="12" font="12"><i>=</i></text>
<text top="589" left="493" width="2" height="13" font="11"><i>.</i></text>
<text top="591" left="496" width="20" height="9" font="0">002).</text>
<text top="620" left="309" width="240" height="9" font="8"><i>3.10. Subgroup Analysis according to Milan Status. </i>In the 4</text>
<text top="631" left="309" width="240" height="9" font="0">patients that exceeded Milan criteria before transplantation,</text>
<text top="642" left="309" width="240" height="9" font="0">2 represented a failed attempt at downstaging and cancer</text>
<text top="654" left="309" width="240" height="9" font="0">progression was observed in 2. Three of the 4 patients (75%)</text>
<text top="665" left="309" width="240" height="9" font="0">exceeding Milan at OLT had HCC discovered at histology.</text>
<text top="677" left="309" width="240" height="9" font="0">At follow-up, HCC recurrence was observed in 2 of these</text>
<text top="688" left="309" width="240" height="9" font="0">patients (50%). Hence, being outside Milan before OLT</text>
<text top="699" left="309" width="240" height="9" font="0">significantly increased risk of cancer recurrence after OLT</text>
<text top="711" left="309" width="126" height="9" font="0">(RR: 6.33, 95% CI: 1.53–26.18).</text>
<text top="722" left="324" width="225" height="9" font="0">In the 22 patients within Milan criteria before trans-</text>
<text top="733" left="309" width="240" height="9" font="0">plantation, 10 (45%) had complete HCC necrosis and all</text>
</page>
</pdf2xml>
